Navigation Links
Cytochroma Announces Appointment of Peter Moldt to Board of Directors
Date:11/25/2009

MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma today announced the appointment of Peter Moldt, PhD to its Board of Directors. Dr. Moldt will replace Mr. Ulrik Spork as the Novo A/S representative on the Company's Board. The number of Board members remains unchanged at six members.

"We are very pleased to welcome Peter Moldt to the board and look forward to benefiting from his experience and guidance as Cytochroma continues to make progress in becoming a leading CKD-focused specialty pharmaceutical company," stated Alan Lewis, PhD, Chairman of Cytochroma's Board of Directors. "We are grateful for the advice that Ulrik Spork has provided to Cytochroma over the past year, and wish him well in the future."

Dr. Moldt has significant experience in corporate strategy, company operations, and drug development. He was most recently CEO of Curalogic A/S, a company he cofounded in 2004 and subsequently took public. Before Curalogic A/S, he was Chief Operating Officer of 7TM Pharma A/S, a company which he cofounded in 2000. Prior to 2000, Dr. Moldt spent 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. Dr. Moldt holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy, and has been a post-doc with Yale University's Department of Organic Chemistry.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
2. Cytochroma opens U.S. headquarters in Illinois
3. Cytochroma Appoints R. Richard Wieland II As CFO
4. Cytochroma Closes $45 Million Series C Financing
5. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
6. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
7. Cytochroma announces appointment of Ulrik Spork to Board of Directors
8. Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... (PRWEB) June 02, 2015 GenoCAD ... synthesis to improve protein expression, announced the formation of ... six executives and entrepreneurs with a broad range of ... , The team includes: , Jimmy Roussel, Entrepreneur ... Roussel has a background in technology and marketing. He ...
(Date:6/1/2015)... 1, 2015 Research ... the addition of the "Oxidative Stress ... Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The global ...
(Date:6/1/2015)... June 1, 2015 GenomeDx Biosciences ... analysis platform, successfully classified various subtypes of ... of certain biomarkers, including one type associated ... unique genomic signature has potential as a ... chemotherapy in patients with muscle-invasive bladder cancers ...
(Date:6/1/2015)... 1, 2015  Novartis is highlighting data from ... an investigational chimeric antigen receptor (CAR) T cell ... of specific types of hard-to-treat non-Hodgkin lymphoma. Findings ... of Pennsylvania,s Perelman School of Medicine (Penn) in ... B-cell lymphoma (DLBCL) and follicular lymphoma (FL) found ...
Breaking Biology Technology:GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... Europe Ongoing , , DALLAS, June 10 ... (OTC Bulletin Board: ACCP) , announced ... States Patent and Trademark Office that two US patents relating to ... for the management of mucositis will issue in June as US ...
... Calif., June 10 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Business Officer of BioMarin, will present a company update at the ... 2009 at 8:30 a.m. ET. , , Interested ... via the investor section of the BioMarin website, www.BMRN.com ...
... 10 Delcath Systems, Inc. (Nasdaq: DCTH ), ... (PHP(TM)) System for the treatment of cancers of the liver, ... to sell 869,565 units, each unit consisting of one of ... common shares, for gross proceeds of approximately $3 million, before ...
Cached Biology Technology:Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM) 2Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM) 3BioMarin to Present at the Jefferies Healthcare Conference 2Delcath Enters Agreement to Sell 869,565 Units 2Delcath Enters Agreement to Sell 869,565 Units 3
(Date:5/26/2015)... 26, 2015 Research and ... of the "Saudi Arabia Biometric Systems Market ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems ... is projected to grow at over 22% CAGR ... attributed to the surging demand for better biometric ...
(Date:5/22/2015)... DALLAS , May 22, 2015 ... Recognition Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by ... End User (Government and Utilities, Consumer and Home) - ... Market to grow from $2.77 Billion in 2015 to ... Browse 79 market data Tables and ...
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... identifies regions of the human genome that regulate gene expression ... number of human diseases, according to researchers at Dukes Institute ... DNA in our bodies is packaged, or tightly structured, said ... of the senior investigators on this study. Our goal was ...
... sliding against joints, ink jets splashing on paperliving ... However important these liquid/solid boundaries may be, conventional ... interfaces in their natural environments. Now, researchers at ... and the University of Minnesota have demonstrated a ...
... According to a study published in Nature by researchers ... the hydrology and chemistry of the Mississippi River, injecting ... discharge during the past 50 years. LSU Professor ... with their colleagues at Yale, tracked changes in the ...
Cached Biology News:Search for the 'on' switches may reveal genetic role in development and disease 2Videos extract mechanical properties of liquid-gel interfaces 2LSU, Yale team study agricultural impact on Mississippi River 2
... pressure gradient system uses three Adept CE ... a flow rate in one microlitre increaments. ... added flexibility. System control and data processing ... interface unit, CE 4900., Column heater/chillers can be ...
... The Adept HPLC range has ... Q-Adept systems, a quaternary low ... binary low pressure mixing pump. ... compact systems add even more ...
capacity 250 mL...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z35,347-7) ...
Biology Products: